lucitanib   Click here for help

GtoPdb Ligand ID: 7649

Synonyms: E-3810 amine | E3810
PDB Ligand
Compound class: Synthetic organic
Comment: Lucitanib is an inhibitor of multiple receptor tyrosine kinases [2] that was investigated for anti-angiogenic and anti-tumourigenic efficacy.
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 4
Hydrogen bond donors 2
Rotatable bonds 8
Topological polar surface area 95.7
Molecular weight 443.18
XLogP 3.6
No. Lipinski's rules broken 0
Click here for help
Canonical SMILES CNC(=O)c1cccc2c1ccc(c2)Oc1ccnc2c1cc(OC)c(c2)OCC1(N)CC1
Isomeric SMILES CNC(=O)c1cccc2c1ccc(c2)Oc1ccnc2c1cc(OC)c(c2)OCC1(N)CC1
InChI InChI=1S/C26H25N3O4/c1-28-25(30)19-5-3-4-16-12-17(6-7-18(16)19)33-22-8-11-29-21-14-24(23(31-2)13-20(21)22)32-15-26(27)9-10-26/h3-8,11-14H,9-10,15,27H2,1-2H3,(H,28,30)
No information available.
Summary of Clinical Use Click here for help
Lucitanib progressed to Phase 2 clinical trial for various advanced cancers, but development has not progressed and there are no active trials registered with (as of Oct 2018). Click here to view's list of lucitanib studies.
Mechanism Of Action and Pharmacodynamic Effects Click here for help
Lucitanib exhibits potent anti-angiogenic and anti-tumour activity, achieved via inhibition of VEGFR, FGFR and PDGFR tyrosine kinases [2]. Lucitanib action is reviewed in [1].